Nature | Vol 577 | 23 January 2020 | 555- Germain, C. et al. Presence of B cells in tertiary lymphoid structures is associated with a
protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189 ,
832–844 (2014). - Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161 ,
1681–1696 (2015). - Cancer Genome Atlas Research Network. Comprehensive molecular characterization of
clear cell renal cell carcinoma. Nature 499 , 43–49 (2013). - Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint
immunotherapy in melanoma. Cell 175 , 998–1013 (2018).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
© The Author(s), under exclusive licence to Springer Nature Limited 2020
(^1) Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center,
Houston, TX, USA.^2 Department of Breast Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, TX, USA.^3 Department of Genitourinary Cancers, The
University of Texas MD Anderson Cancer Center, Houston, TX, USA.^4 Department of Genomic
Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
(^5) Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD
Anderson Cancer Center, Houston, TX, USA.^6 Department of Medicine, Massachusetts
General Hospital Cancer Center, Boston, MA, USA.^7 Broad Institute of the Massachusetts
Institute of Technology, Boston, MA, USA.^8 Department of Immunology, The University of
Texas MD Anderson Cancer Center, Houston, TX, USA.^9 Department of Bioinformatics and
Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX,
USA.^10 Department of Melanoma Medical Oncology, The University of Texas MD Anderson
Cancer Center, Houston, TX, USA.^11 Department of Cancer Biology, The University of Texas MD
Anderson Cancer Center, Houston, TX, USA.^12 Department of Thoracic / Head and Neck
Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
(^13) Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. (^14) Department of
Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
(^15) Department of Translational and Molecular Pathology, The University of Texas MD Anderson
Cancer Center, Houston, TX, USA.^16 Immunology Program, Sloan Kettering Institute, Memorial
Sloan Kettering Cancer Center, New York, NY, USA.^17 Nanostring Technologies, Seattle, WA,
USA.^18 Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute,
Amsterdam, The Netherlands.^19 Departments of Medicine, Surgery, Immunology and Clinical
and Translational Science, University of Pittsburgh, Pittsburgh, PA, USA.^20 Department of
Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer
Center, Houston, TX, USA.^21 INSERM, Cordeliers Research Center, Team Cancer, Immune
Control and Escape, Paris, France.^22 University Paris Descartes Paris 5, Sorbonne Paris Cite,
Centre de Recherche des Cordeliers, Paris, France.^23 Programme Cartes d’Identité des
Tumeurs, Ligue Nationale Contre le Cancer, Paris, France.^24 These authors contributed
equally: Beth A. Helmink, Sangeetha M. Reddy, Jianjun Gao, Shaojun Zhang, Rafet Basar.
(^25) These authors jointly supervised this work: Katayoun Rezvani, Padmanee Sharma, Michael T.
Tetzlaff, Linghua Wang, Jennifer A. Wargo. *e-mail: [email protected]; jwargo@
mdanderson.org